$PVCT Balance Sheet | Understand Stock

$PVCT

$0.06 +$0.00 (3.9%) Close

$PVCT Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
Assets
Current Assets:
Short-term receivables - legal fees, settlement and other, net
Cash
Restricted cash
Short-term receivables
Prepaid expenses and other current assets
Total Current Assets

Equipment and furnishings, less accumulated depreciation of $120,945 and $120,013, respectively
Operating lease right-of-use asset
Total Assets
Liabilities and Stockholders’ Deficit
Current Liabilities:
Accounts payable - trade
Deposit for purchase of Series D-1 Preferred Stock
Accounts payable
Deposit for Series D-1 Preferred Stock
Unearned grant revenue
Accrued interest
Nonrelated Party
Related Party
Total accrued interest
Accrued interest - related parties
Other accrued expenses
Notes payable
Convertible notes payable
Nonrelated Party
Related Party
Total convertible notes payable
Convertible notes payable - related parties
Related Party
Total convertible notes payable - related parties
Operating lease liability, current portion
Total Current Liabilities
Notes payable, non-current portion
Operating lease liability, non-current portion

Total Liabilities
Stockholders’ Deficit:
Preferred Stock Value
Series D Convertible Preferred Stock
Series D-1 Convertible Preferred Stock
Series D-1 Convertible Preferred Stock

Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 420,279,879 shares issued and outstanding at June 30, 2026 and December 31, 2025
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total Provectus Biopharmaceuticals, Inc., Stockholders’ Deficit
Non-controlling interest in subsidiary
Total Stockholders’ Deficit
Total Liabilities and Stockholders’ Deficit

Comments